• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Dec. 5, 2011

View Archived Issues

CBO Forecasts Cloudy Skies For Pediatric Exclusivity

WASHINGTON – With the sun setting next year on two major pediatric drug acts, a debate over pediatric exclusivity hovers on the horizon. Read More

Burzynski Flaunts Convention With Pay-to-Play Clinical Trials

Two highly publicized fundraisers based in the UK have drawn attention to an unusual practice by the Burzynski Research Institute Inc. in Houston, triggering a storm of criticism in the blogosphere. The institute charges exhorbitant fees to patients for participation in its many ongoing trials of its investigative antineoplaston cancer therapy, even though there are no randomized, controlled trials proving the effectiveness of the therapy in the peer-reviewed scientific literature. Read More

Engineering Stem Cells for Lasting Melanoma Vaccine

Researchers at the University of California, Los Angeles, reported last week that they have been able to induce long-lasting T-cell responses to melanoma cells by engineering not the T cells themselves, but their progenitor cells. Read More

X-Body Platform Yields First Lead Compound for AMD

At the IBC Antibody Engineering Conference in San Diego, X-Body Biosciences reported that it has discovered and optimized its first lead anti-angiogenesis compound, XB2202, from its DNA display and sequencing platform. The compound satisfied the requirements for a lead compound, including inhibition of receptor phosphorylation in renal carcinoma cells and inhibition of retinal pericyte migration, through its binding of platelet-derived growth factor receptor beta (PDGFRB). Read More

Other News To Note

• Northwest Biotherapeutics Inc., of Bethesda, Md., said it implemented a restructuring to reduce its liabilities from $48 million to $16.5 million, removing $31.5 million through settlement, retirement and conversion. The firm said the move will strengthen its balance sheet as it accelerates its 240-patient Phase II trial of its lead dendritic cell-based vaccine in glioblastoma multiforme. Northwest also recently received clearance for a Phase III trial in prostate cancer. Read More

Clinic Roundup

• Oncolytics Biotech Inc., of Calgary, Alberta, said interim Phase II data showed intravenous administration of Reolysin in combination with Gemzar (gemcitabine, Eli Lilly and Co.) in patients with advanced pancreatic cancer met the study's primary endpoint. Read More

Stock Movers

Read More

Bench Press

Scientists from the Japan Science and Technology Agency and the University of Tokyo have identified a new player in bone marrow that keeps blood stem cells going: Schwann cells, a type of glial, or brain support cell. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe